Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 17/20 | 0.73 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.67 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7208989 | 0.89 | IMPDH2 (0.73) | IMPDH2IMPDH1MAPTMEN1HTT | |
| SCHEMBL7729166 | 0.86 | IMPDH2 (0.57) | IMPDH2SETD7IMPDH1 | |
| SCHEMBL4258273 | 0.85 | IMPDH2 (0.80) | IMPDH2IMPDH1 | |
| SCHEMBL4253104 | 0.85 | IMPDH2 (0.80) | IMPDH2IMPDH1 | |
| SCHEMBL1474411 | 0.85 | IMPDH2 (1.00) | IMPDH2IMPDH1 | |
| SCHEMBL7543846 | 0.81 | IMPDH2 (0.88) | IMPDH2IMPDH1 | |
| SCHEMBL30292051 | 0.80 | IMPDH2 (0.60) | IMPDH2IMPDH1MAPTMEN1HTT | |
| SCHEMBL3863160 | 0.80 | IMPDH2 (0.60) | IMPDH2IMPDH1MAPTMEN1HTT | |
| SCHEMBL1475788 | 0.80 | IMPDH2 (1.00) | IMPDH2IMPDH1 | |
| SCHEMBL5010235 | 0.78 | IMPDH2 (0.63) | IMPDH2IMPDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | GABBR1, GABBR2, CHRM2 | IMPDH2 2643/4885SETD7 1077/4885IMPDH1 2186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.